<DOC>
	<DOCNO>NCT01616290</DOCNO>
	<brief_summary>The purpose study determine safe feasible apply PRT-201 adventitia artery follow successful angioplasty ( PTA ) .</brief_summary>
	<brief_title>Pilot Study PRT-201 Following Angioplasty Patients With Peripheral Artery Disease ( PAD )</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Age least 18 year 2 . Clinical diagnosis PAD , secondary atherosclerosis affect low limb 3 . Rutherford classification 24 ( moderate claudication ischemic rest pain ) 4 . ABI &lt; 0.90 rest exercise , toebrachial index &lt; 0.70 , radiographic evidence PAD correlate clinical symptom 5 . De novo lesion , previously treat angioplasty atherectomy 6 . Greater 70 % stenosis SFA PA , target lesion length 10 cm less , least one patent runoff vessel . Short segment occlusion ( &lt; 10 cm ) acceptable 7 . If female childbearing potential ( premenopausal surgically sterile ) must negative pregnancy test screen visit willing use contraception time screen visit 1 week follow study drug administration . Acceptable method birth control include abstinence , barrier method spermicide , implant , injectables , oral contraceptive , intrauterine device , vasectomize partner 8 . Ability understand comply requirement entire study communicate study team 9 . Ability provide write informed consent use document approve required institutional review board 1 . Previous treatment PRT201 2 . Patients arterial insufficiency lower extremity result immunologic inflammatory nonatherosclerotic disorder ( e.g . Buerger 's disease , vasculitis ) 3 . Current severe critical limb ischemia define ulceration gangrene 4 . Planned atherectomy artery index leg 5 . Prior plan stenting target lesion 6 . Prior bypass surgery target SFA PA 7 . Severe concentric medial calcification target lesion think interfere drug delivery adventitia define subjectively Investigator base fluoroscopic appearance . 8 . History metastatic cancer 9 . Presence aortic peripheral artery aneurysm 10 . Platelet count &lt; 130K , hematocrit &lt; 30 % , bilirubin ALT &gt; 3.0 time upper limit normal 11 . Pregnancy , lactation plan become pregnant course study 12 . Presence significant medical condition might significantly confound collection safety efficacy data study 13 . Treatment investigational drug within previous 30 day investigational antibody therapy within 90 day prior sign inform consent 14 . Known allergy contrast medium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>peripheral artery disease</keyword>
	<keyword>PAD</keyword>
	<keyword>claudication</keyword>
	<keyword>angioplasty</keyword>
	<keyword>percutaneous transluminal angioplasty</keyword>
	<keyword>PTA</keyword>
	<keyword>superficial femoral artery</keyword>
	<keyword>SFA</keyword>
	<keyword>popliteal artery</keyword>
	<keyword>PA</keyword>
	<keyword>PRT-201</keyword>
	<keyword>restenosis</keyword>
	<keyword>vonapanitase</keyword>
</DOC>